10-nitro-oleic-acid and Asthma

Bile acid profiles are altered in obese individuals with asthma. Thus, we sought to better understand how obesity-related systemic changes contribute to lung pathophysiology. We also test the therapeutic potential of nitro-oleic acid (NO

Topics: Adolescent; Adult; Animals; Anti-Asthmatic Agents; Antigens, Dermatophagoides; Asthma; Bile Acids and Salts; Diet, High-Fat; Drug Evaluation, Preclinical; Fatty Acids; Female; Forced Expiratory Volume; Glycocholic Acid; Humans; Liver; Lung; Male; Mice; Mice, Inbred C57BL; Middle Aged; Nitro Compounds; Obesity; Oleic Acids; Respiratory Hypersensitivity; Thinness; Ursodeoxycholic Acid; Vital Capacity; Young Adult

Asthma is a serious, growing problem worldwide. Inhaled steroids, the current standard therapy, are not always effective in this chronic inflammatory disease and can cause adverse effects. We tested the hypothesis that nitrated fatty acids (NFAs) may provide an effective alternative treatment. NFAs are endogenously produced by nonenzymatic reaction of NO with unsaturated fatty acids and exert anti-inflammatory actions both by activating the nuclear hormone receptor peroxisome proliferator-activated receptor (PPAR)γ and via PPAR-independent mechanisms, but whether they might ameliorate allergic airway disease was previously untested. We found that pulmonary delivery of the NFA 10-nitro-oleic acid (OA-NO2) reduced the severity of murine allergic airway disease, as assessed by various pathological and molecular markers. Fluticasone, an inhaled steroid commonly used to treat asthma, produced similar effects on most end points, but only OA-NO2 induced robust apoptosis of neutrophils and their phagocytosis by alveolar macrophages. This suggests that OA-NO2 may be particularly effective in neutrophil-rich, steroid-resistant severe asthma. In primary human bronchial epithelial cells, OA-NO2 blocked phosphorylation and degradation of IκB and enhanced inhibitory binding of PPARγ to NF-κB. Our results indicate that the NFA OA-NO2 is efficacious in preclinical models of allergic airway disease and may have potential for treating asthma patients.

Topics: Animals; Anti-Inflammatory Agents; Asthma; Blotting, Western; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Fatty Acids; Fluorescent Antibody Technique; Humans; Immunoprecipitation; Male; Mice; Mice, Inbred C57BL; Microscopy, Confocal; Oleic Acids; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction